Twentyeight Health vs Regeneron Pharmaceuticals
Side-by-side comparison of AI visibility scores, market position, and capabilities
Twentyeight Health provides affordable telehealth and mail-order pharmacy for contraception, STI testing, and reproductive health to underserved and low-income women.
About
Twentyeight Health is a reproductive health telehealth company founded in 2019 that focuses specifically on expanding access to contraception and reproductive healthcare for underserved women, including those on Medicaid, without insurance, or in rural areas. The platform provides online consultations with licensed providers for birth control prescriptions, STI testing kits by mail, emergency contraception, and general reproductive health questions at accessible price points with Medicaid acceptance. Twentyeight raised $25M and has enrolled hundreds of thousands of patients, with a focus on the communities most affected by reproductive healthcare access gaps. The company differentiates from other telehealth platforms by prioritizing Medicaid acceptance, multilingual care, and a health equity mission rather than serving primarily the commercially insured population. Twentyeight operates in most US states and has built relationships with state health departments and safety-net healthcare organizations. As access to reproductive healthcare has become more constrained in some US states, Twentyeight's telehealth model has become an increasingly critical access point for patients who cannot easily reach in-person reproductive health services.
Regeneron (REGN) reported $13.9B revenue in FY2024, up 7% YoY. Top biotech company. Dupixent franchise >$14B. Leaders in eye disease, immunology, oncology. HQ: Tarrytown, NY.
About
Regeneron Pharmaceuticals, Inc. is a leading biotechnology company specializing in the discovery, development, and commercialization of medicines for serious diseases, headquartered in Tarrytown, New York. Founded in 1988 by Leonard Schleifer and George Yancopoulos, Regeneron developed its own proprietary drug discovery technology platform (VelociGene, VelocImmune) that has enabled the development of multiple breakthrough medicines. The company reported revenues of $13.9B in FY2024, up 7% year-over-year.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Integrations
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.